



PA.143CP2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Zaghouani, H.	)	Group Art Unit 1644
			)	
Appl. No.	:	09/111,123	)	
			)	
Filed	:	July 6, 1998	)	
			)	
For	:	Compounds, Compositions and	)	
		Methods for the Endocytic	)	
		Presentation of Immunosuppressive	)	
		Factors	)	
Examiner	:	P. Nolan	)	
			)	

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, P. O. Box 1450, Alexandria, VA 22313-1450 on July 11, 2003.

Nikki Weaver  
Nikki Weaver

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

Commissioner of Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated January 13, 2003, applicant submits the following response:

**In the Claims:**

Please amend claim 1 as follows:

1. (Thrice Amended) A fusion protein for the alleviation of symptoms associated with an autoimmune disorder comprising an immunoglobulin or portion thereof linked to one or more T cell receptor antagonists wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and being endocytosed by an antigen presenting cell to present said one or more T cell receptor antagonists in association with endogenous MHC Class II molecules, thereby preventing activation of T cells specific for said T cell receptor antagonist.